Previous investigations show that intracerebroventricular administration of a potent inhibitor of fatty acid synthase, C75, increases the level of its substrate, malonyl-CoA, in the hypothalamus. The ''malonyl-CoA signal'' is rapidly transmitted to skeletal muscle by the sympathetic nervous system, increasing fatty acid oxidation, uncoupling protein-3 (UCP3) expression, and thus, energy expenditure. Here, we show that intracerebroventricular or intraperitoneal administration of C75 increases the number of mitochondria in white and red (soleus) skeletal muscle. Consistent with signal transmission from the hypothalamus by the sympathetic nervous system, centrally administered C75 rapidly (<2 h) up-regulated the expression (in skeletal muscle) of the ␤-adrenergic signaling molecules, i.e., norepinephrine, ␤3-adrenergic receptor, and cAMP; the transcriptional regulators peroxisomal proliferator activator regulator ␥ coactivator 1␣ (PGC-1␣) and estrogen receptor-related receptor ␣ (ERR␣); and the expression of key oxidative mitochondrial enzymes, including pyruvate dehydrogenase kinase, mediumchain length fatty acyl-CoA dehydrogenase, ubiquinone-cytochrome c reductase, cytochrome oxidase, as well as ATP synthase and UCP3. The role of PGC-1␣ in mediating these responses in muscle was assessed with C2C12 myocytes in cell culture. Consistent with the in vivo response, adenovirus-directed expression of PGC-1␣ in C2C12 muscle cells provoked the phosphorylation͞ inactivation and reduced expression of acetyl-CoA carboxylase 2, causing a reduction of the malonyl-CoA concentration. These effects, coupled with an increased carnitine palmitoyltransferase 1b, led to increased fatty acid oxidation. PGC-1␣ also increased the expression of ERR␣, PPAR␣, and enzymes that support mitochondrial fatty acid oxidation, ATP synthesis, and thermogenesis, apparently mediated by an increased expression of UCP3. C75 ͉ energy expenditure ͉ sympathetic nervous system ͉ uncoupling protein 3 ͉ C2C12 myocytes T he level of hypothalamic malonyl-CoA, an intermediate in the pathway of de novo fatty acid synthesis, is an indicator of whole-body energy status (1-5). The malonyl-CoA concentration responds to changes in energy balance by signaling to higher brain centers that regulate feeding behavior and to peripheral tissues that alter energy expenditure (1). Hypothalamic malonylCoA is also responsive to centrally administered inhibitors of fatty acid synthesis (4) and to the ectopic expression of malonylCoA decarboxylase in the ventral hypothalamus (5, 6). The malonyl-CoA signal is rapidly relayed by the sympathetic nervous system (SNS) to skeletal muscle, where energy expenditure is up-regulated through increased fatty acid oxidation and thermogenic uncoupling mediated by uncoupling protein 3 (UCP3) (7, 8) . Thus, a regulatory linkage exists between the anabolic pathway of fatty acid synthesis in the hypothalamus and food intake and energy expenditure.
T
he level of hypothalamic malonyl-CoA, an intermediate in the pathway of de novo fatty acid synthesis, is an indicator of whole-body energy status (1) (2) (3) (4) (5) . The malonyl-CoA concentration responds to changes in energy balance by signaling to higher brain centers that regulate feeding behavior and to peripheral tissues that alter energy expenditure (1) . Hypothalamic malonylCoA is also responsive to centrally administered inhibitors of fatty acid synthesis (4) and to the ectopic expression of malonylCoA decarboxylase in the ventral hypothalamus (5, 6) . The malonyl-CoA signal is rapidly relayed by the sympathetic nervous system (SNS) to skeletal muscle, where energy expenditure is up-regulated through increased fatty acid oxidation and thermogenic uncoupling mediated by uncoupling protein 3 (UCP3) (7, 8) . Thus, a regulatory linkage exists between the anabolic pathway of fatty acid synthesis in the hypothalamus and food intake and energy expenditure.
A substantial body of evidence indicates that malonyl-CoA acts as a signaling intermediary in this regulatory system. Centrally (intracerebroventricularly; i.c.v.) administered fatty acid synthase (FAS) inhibitors, such as C75 or cerulenin, rapidly increase the level of malonyl-CoA (substrate of FAS) in the hypothalamus and suppress food intake (4) . Moreover, these effects can be reversed by blocking malonyl-CoA formation with an inhibitor [i.e., 5-(tetradecyloxy)-2-furoic acid; TOFA] of acetyl-CoA carboxylase (ACC) (4) . Hence, the central administration of TOFA prevents the C75-induced rise of malonylCoA in the hypothalamus and the decrease of food intake. These effects take place rapidly, i.e., Յ2 h after the administration of the inhibitors. Consistent with a role for hypothalamic malonylCoA in the signaling system is the finding that bilateral stereotactic injection of an adenoviral malonyl-CoA decarboxylase vector into the ventral hypothalamus (a region encompassing the arcuate nucleus) to lower malonyl-CoA level causes hyperphagia and weight gain (5, 6) , and it reverses the suppression of food intake by the FAS inhibitor (5) . After an extended period, this treatment produces large weight gains and the accumulation of body fat (6) . Further, it was recently found that a conditional knockdown of FAS in the hypothalamus causes decreased food intake and body weight and increased energy expenditure (C. Semenkovich, personal communication). Associated with this down-regulation of hypothalamic FAS is a marked increase in malonyl-CoA in the hypothalamus (Z. Hu and M.D.L., unpublished results). Finally, physiological changes that are known to affect appetite correlate closely with changes in the hypothalamic level of malonyl-CoA (1). Thus, fasting increases appetite and decreases hypothalamic malonyl-CoA, whereas refeeding after fasting increases hypothalamic malonyl-CoA and decreases appetite (4) . Together, these findings show that malonyl-CoA is an indicator of energy status in the hypothalamic regulatory system, which controls feeding behavior.
Closely associated with its role in regulating food intake, increasing hypothalamic malonyl-CoA rapidly inactivates neuropeptide Y-expressing neurons in the arcuate nucleus (as assessed by c-Fos expression), and it decreases the expression of the orexigenic neuropeptides, neuropeptide Y and Agoutirelated protein (4, 10) . Conversely, increasing hypothalamic Conflict of interest statement: Under a licensing agreement between FASgen and The Johns Hopkins University, M.D.L. is entitled to a share of royalty received by the University on products embodying the technology described in this article. Terms of this arrangement are managed by the University in accordance with its conflict-of-interest policies.
Abbreviations: ACC, acetyl-CoA carboxylase; ATP5␥1, ATP synthase subunit 5␥1; Cox, cytochrome oxidase; CPT1b, carnitine palmitoyltransferase 1b; ERR␣, estrogen receptorrelated receptor ␣; FAS, fatty acid synthase; i.c.v., intracerebroventricular; IDH3␣, isocitrate dehydrogenase 3␣; MCAD, medium-chain length fatty acyl-CoA dehydrogenase; PDK4, pyruvate dehydrogenase kinase 4; PGC-1␣, PPAR␥ coactivator-1␣; PPAR, peroxisomal proliferator activator regulator; SNS, sympathetic nervous system; UCP3, uncoupling protein 3; UQCR, ubiquinone-cytochrome c reductase; malonyl-CoA increases expression of the anorexigenic neuropeptides, ␣-melanocyte-stimulating hormone and cocaineand amphetamine-regulated transcript, changes that decrease in food intake. Taken together, these responses provide convincing evidence that malonyl-CoA regulates feeding behavior.
In the present work, we report that the central administration of C75 up-regulates the expression of the transcriptional coactivator, peroxisomal proliferator activator ␥ coactivator 1␣ (PGC-1␣) and of peroxisomal proliferator activator ␣ (PPAR␣) in skeletal muscle. We also show that the ectopic expression of PGC-1␣ in a muscle cell line activates fatty acid oxidation and induces expression of UCP3 and PPAR␣. PGC-1␣ is known to activate the transcription of genes that promote adaptive thermogenesis in both brown adipose tissue and skeletal muscle, and it stimulates mitochondrial biogenesis (11) (12) (13) . PGC-1␣ is a transcriptional coactivator that interacts with different transcription factors, e.g., PPAR␥, PPAR␣, and thyroid hormone receptor, bound to the promoters of target genes that carry out its metabolic effects. Recently, the nuclear hormone receptor estrogen receptor-related receptor ␣ (ERR␣) was found to facilitate the actions of PGC-1␣ (14) (15) (16) . These findings illustrate the importance of these transcriptional regulators in the control of energy homeostasis.
During our studies on the linkage of effectors that up-regulate hypothalamic malonyl-CoA and their peripheral effects, we observed that repetitive i.c.v. or i.p. administration of the FAS inhibitor C75 deepened the red coloration of skeletal muscle, notably the gastrocnemius muscle (Fig. 1A) . This observation suggested that the increased color density of the muscle might be the result of an increased mitochondrial cytochrome content of the tissue because it correlated closely with increased mitochondrial fatty acid oxidation and increased expression of PGC-1␣ and UCP3 (8) . Here we show that inhibition of FAS by the central administration of C75 rapidly increases hypothalamic malonyl-CoA and triggers peripheral effects on skeletal muscle. These effects include a decrease of muscle malonyl-CoA, the induction of mitochondrial biogenesis, and the expression of enzymes of mitochondrial fatty acid oxidation. Moreover, these effects can be recapitulated in C2C12 muscle cells ex vivo by the forced expression of PGC-1␣.
Results

Inhibition of FAS in the Central Nervous System Increases the Number
of Mitochondria in White and Red Skeletal Muscle. Mice given repetitive injections (administered either i.p. or i.c.v.) of the potent FAS inhibitor C75 for 3-4 days exhibit a marked reduction of body weight and food intake ( Fig. 7 , which is published as supporting information on the PNAS web site). However, by the 3rd to 4th day after C75 treatment, mice become resistant to the inhibitor, and food intake returns to 60-65% of controls (Fig. 7) . Despite having acquired resistance to C75, body weight continues to decrease. This response is similar to that reported earlier, which showed that pair-fed (isocaloric food intake) controls lost less body weight than C75-treated mice (7, 17) . These and other results (8, 18) indicate that the energy expenditure of C75-treated mice is greater than that of controls.
It was observed that C75 treatment (i.p. or i.c.v. injection) increased the ''redness'' of skeletal muscle ( Fig. 1 A) possibly because of increased cytochrome content, raising the possibility that the number of mitochondria might have increased. To test this possibility, white (tibialis anterior) and red (soleus) skeletal muscle tissue from C75-treated or control mice was subjected to electron microscopy. Both white and red soleus (not shown) muscle from C75-treated mice contained more mitochondria per unit area than vehicle-injected controls. Mitochondrial content was quantified by counting mitochondria in five fields (25 m 2 ) in electron micrographs for each treatment and muscle type (Fig.  1B) . In all cases, the number of mitochondria per unit area was substantially higher (by 30-88%) in muscle sections from C75-treated mice.
Inhibition of FAS in the CNS Induces the Expression of Genes of
Oxidative Energy Metabolism in Skeletal Muscle. Our previous studies showed that the central (i.c.v.) administration of C75 rapidly (Յ2 h) increased the malonyl-CoA level in the hypothalamus, which was accompanied by the rapid up-regulation of fatty acid oxidation in skeletal muscle (8) . Thus, the C75-induced increase of hypothalamic malonyl-CoA led to an increase in the rate of oxidation of [ 14 C]oleate to 14 CO 2 both by intact mice and by skeletal muscle explants from C75-treated mice. These effects occurred more rapidly than the increase in mitochondria number after repetitive daily injections of C75 (above). Nevertheless, both effects appeared to be directed at increasing fatty acid oxidation.
Additional experiments were conducted to assess the effect of centrally administered C75, which increases hypothalamic malonyl-CoA (4), on the expression of a group of factors and enzymes that are known to promote or be associated with fatty acid oxidation in skeletal muscle. We first verified that the i.c.v. administration of the FAS inhibitor to fasted mice rapidly (Յ2 h) up-regulates malonyl-CoA to a hypothalamic level comparable with that in mice that have been refed after fasting ( Fig. 2A) . Our previous studies showed that increasing hypothalamic malonyl-CoA reduces food intake (4) . The present studies also show that the rise in hypothalamic malonyl-CoA is rapidly followed by a decrease of malonyl-CoA in skeletal muscle. That this decrease is the result of stimulation mediated through the SNS is shown by the finding that the ␤-blocker propranolol prevents the effect of centrally administered C75 (Fig. 2B) . Administration of the ␤-blocker alone, however, did not lower malonyl-CoA, but it blunted the malonyl-CoA-lowering effect of C75 in muscle. Likewise, up-regulation of expression of the UCP3 gene, the muscle-specific thermogenic mitochondrial protein shown previously to be up-regulated by centrally administered C75 (8) , was blocked by the propranolol (Fig. 2C) . Consistent with these apparent SNS-mediated effects, i.c.v. administration of C75 rapidly increased the levels of ␤-adrenergic signaling molecules in skeletal muscle, including norepinephrine, the ␤ 3 -adrenergic receptor, and cAMP (Fig. 2 D-F) .
Moreover, genes that regulate or are involved in fatty acid oxidation, the tricarboxylic acid cycle, and oxidative phosphorylation were also rapidly expressed in skeletal muscle after the i.c.v. administration of the FAS inhibitor (Fig. 3) . Notable among these genes are those that encode ERR␣ and PGC-1␣ (Fig. 3) , factors known to regulate numerous downstream genes that promote fatty acid oxidation and mitochondrial energy metabolism (14, 19, 20) . Thus, the expression of carnitine palmitoyltransferase 1b (CPT1b), which initiates the translocation of fatty acids into mitochondria, and medium-chain length fatty acylCoA dehydrogenase (MCAD) are markedly up-regulated (Fig.  3) . Also up-regulated are the genes that encode pyruvate dehydrogenase kinase4 (PDK4), mitochondrial isocitrate dehydrogenase (IDH3␣), ubiquinone-cytochrome c reductase (UQCR), cytochrome oxidase subunits 2 and 5 (Cox2 and Cox5), ATP synthase subunit 5␥1 (ATP5␥1) (Fig. 3) , and UCP3 (8).
Effect of Ectopically Expressed PGC-1␣ on Fatty Acid Oxidation in
Muscle Cells in Culture. Previously (8) we showed that increasing malonyl-CoA in the hypothalamus generates a signal that is transmitted by the SNS to skeletal muscle to activate fatty acid oxidation. As described above, these events correlated closely with the up-regulation of PGC-1␣ expression in skeletal muscle (Fig. 3) . To verify that PGC-1␣ triggered the events that led to increased mitochondrial fatty acid oxidation in vivo, we attempted to recapitulate these conditions with muscle cells ex vivo. PGC-1␣ was ectopically expressed in C2C12 muscle cells with an adenoviral vector (Fig. 4) . Expression of PGC-1␣ caused a marked increase in two transcription factors, ERR␣ and PPAR␣ (Fig. 4B) , which are known to activate many genes involved in mitochondrial fatty acid oxidation and mitochondrial energy metabolism (14, 19 -21) . Closely associated with this activation is an increase of fatty acid oxidation, as indicated by the oxidation of [1- 14 C]oleate to 14 CO 2 (Fig. 5A ). This increase was correlated with a large (Ϸ10-fold) increase in the expression of the CPT1b gene (Fig. 5B ) and a decrease in malonyl-CoA (Fig. 5E ), which is of particular importance because CPT1b facilitates the translocation of fatty acids across the mitochondrial membranes into the matrix, the site of ␤-oxidation (22) (23) (24) (25) . CPT1b is subject to allosteric inhibition by malonyl-CoA, a product of the ACC2-catalyzed reaction. Both the expression (Fig. 5C ) and apparent activity of ACC2 (caused by phosphorylation; Fig. 5D ) were markedly reduced by the expression of PGC-1␣ in C2C12 muscle cells. These changes lower malonyl-CoA in cells (Fig. 5E) , which further promotes mitochondrial fatty acid translocation and oxidation.
PGC-1␣ is known to activate the expression of ERR␣, and the two factors act together to activate expression of the PPAR␣, MCAD, PDK4, and UCP3 genes (14 -16) , all of which participate in mitochondrial energy metabolism. As shown in Fig. 4B , ectopic expression of PGC-1␣ in C2C12 muscle cells induces the expression of these genes ( Fig. 4B and Fig. 8 , which is published as supporting information on the PNAS web site). Additionally, the expression of a number of key tricarboxylic acid cycle genes (PDK4, which inactivates pyruvate dehydrogenase, and IDH3␣), electron transport (UQCR, Cox2, and Cox5), and oxidative phosphorylation (ATP5␥1) are coordinately up-regulated (Fig. 6 ). These findings support the hypothesis that an increase in hypothalamic malonyl-CoA leads to the up-regulation of PGC-1␣ in skeletal muscle, which in turn activates mitochondrial biogenesis and the enzymatic machinery of fatty acid oxidation and energy expenditure. Discussion A large body of evidence implicates malonyl-CoA as a regulatory link between fatty acid synthesis in the hypothalamus and feeding behavior and peripheral energy expenditure. Perturbation of the hypothalamic malonyl-CoA concentration alters feeding behavior and energy expenditure (i) by physiological means (e.g., fasting and refeeding) (4); (ii) with pharmacologic agents (e.g., FAS and ACC inhibitors) (3, 4); (iii) by genetic disruption of hypothalamic FAS expression (C. Semenkovich, personal communication); and (iv) by ectopic expression of malonyl-CoA decarboxylase in the ventral hypothalamus (5, 6). Thus, as hypothalamic malonyl-CoA rises, food intake is suppressed, and energy expenditure is increased. Although food intake is suppressed by the administration of a FAS inhibitor (i.e., C75) to mice (Fig. 7) , inhibitor-treated mice lose more body weight than pair-fed (isocaloric intake) or fasted mice (17) . Such findings were not anticipated because the normal response to fasting is to increase appetite and decrease energy expenditure, a mechanism that conserves energy in the fasted state. It appears that C75 is able to override this mechanism. Therefore, the negative energy balance caused by FAS inhibitors is not entirely the result of suppressed food intake but also increased energy expenditure. Consistent with these findings, indirect calorimetry measurements showed that administration of C75 increases whole-body O 2 consumption (18) . In this work, we show that the cause of these changes in energy expenditure is increased fatty acid oxidation in skeletal muscle brought about by elevated expression of enzymes that regulate and oxidize fatty acids and by an increase in mitochondrial biogenesis. These findings and our previous ones (8) as well as those of others (for reviews, see refs. 1 and 2) support the model illustrated in Fig. 6 .
The malonyl-CoA signal, initiated by the central administration of an FAS inhibitor (or by physiological changes such as fasting and feeding) is rapidly (Յ2 h) communicated to skeletal muscle, where fatty acid oxidation (8) and the expression of the genes relevant to this process are up-regulated (Figs. 2 and 3) . The signal appears to be transmitted by the SNS because the ␤-blocker propranolol (Fig. 2 B and C) and the ␣-blocker phentolamine (8) , prevent the C75-induced effects on skeletal muscle gene expression, e.g., blocking the rise of UCP3 expression. Closely correlated with these changes are rapid increases in the levels of effectors of the ␤-adrenergic signaling system in muscle, i.e., norepinephrine and cAMP; the expression of the ␤-adrenergic receptor; and the phosphorylation of ACC (8), an established target of A-kinase (26, 27) . Likewise, centrally administered C75 triggers the expression of the genes encoding a group of enzymes involved in mitochondrial fatty acid oxidation and oxidative phosphorylation (Fig. 3) . It should be noted that leptin also acts through the hypothalamic-SNS axis, which activates the phosphorylation of ACC and fatty acid oxidation in skeletal muscle (28) .
Furthermore, repetitive administration of C75 over a 3-to 4-day period induced mitochondrial biogenesis, as indicated by a marked increase in the number of mitochondria in white and red (soleus) muscle (Fig. 1B) . This response is most likely the result of the more rapid (Ͻ2 h) up-regulation of PGC-1␣ and ERR␣ expression in muscle (Fig. 3 and ref. 8) , which is consistent with the finding that overexpression the PGC-1␣ gene in muscle of transgenic mice induces muscle fiber-type switching (29) . Thus, the PGC-1␣ transgene induced conversion of type II (fast-twitch) white muscle to type I (slow-twitch) red muscle, the latter having more mitochondria and therefore, being more oxidative (19) . Not surprisingly, we found that the expression of PGC-1␣ and ERR␣ and the complement of genes these transcriptional activators up-regulate occurs rapidly (Յ2 h) (Fig. 3) , whereas mitochondrial biogenesis occurs more slowly.
PGC-1␣ is a documented transcriptional coactivator for the UCP3 and PPAR␣ genes, both of which were rapidly upregulated by the central administration of C75 (Fig. 2C and ref.  8 ). Both down-regulation of malonyl-CoA (Fig. 2B ) and the expression of UCP3 (Fig. 2C) , the muscle-selective mitochondrial uncoupling protein, are prevented by the ␤-blocker propranolol and also by an ␣-blocker, as reported previously (8) . Thus, the SNS appears to be necessary for transmission of the malonyl-CoA signal from brain to skeletal muscle. Like the other UCPs, UCP3 is thought to dissipate the proton gradient across the inner mitochondrial membrane to produce heat, rather than ATP (30, 31) . Such a thermogenic response might be expected to contribute to whole-body energy expenditure. Because UCP3 is expressed primarily in skeletal muscle, the major tissue mass in most vertebrates, up-regulation of UCP3 may be responsible at least in part for the C75-induced increase in energy expenditure. Fatty acids are needed to fuel this thermogenic response (32) . Closely correlated to the upregulation of UCP3, induced by centrally administered C75, is an increase of fatty acid oxidation by skeletal muscle (8) and in C2C12 muscle cells in culture (Fig. 6) .
The signaling molecule with which malonyl-CoA interacts in hypothalamic neurons to initiate these responses has not yet been identified. We suggest that the recently discovered brain-specific enzyme, CPT1c (33, 34) , may be this signaling molecule (Fig. 6 ). Several lines of evidence are consistent with this speculation. First, CPT1c binds malonyl-CoA and is expressed in regions of the ventral hypothalamus, notably the arcuate nucleus, that are critical for the control of energy homeostasis (34) . Consistent with a role as an energy-sensing malonyl-CoA target, CPT1c-null mice eat less and are smaller than wild-type mice (34) . In contrast, however, CPT1c-null mice gain considerably more weight than wild-type controls when fed a high-fat diet, suggesting that the CPT1c gene product provides resistance to the effects of a high fat intake (34) . Finally, CPT1c-null mice exhibit decreased rates of fatty acid oxidation, which is consistent with a role in the control of energy expenditure.
Experimental Procedures
Isolation of RNA, real-time RT-PCR measurement, Western blotting, and fatty acid oxidation were performed as described in ref. 4 . The nucleotide sequences of the primers were as described in ref. 14. In addition, the following primers were used: UCP3 forward primer, 5Ј-TGGCCCAACATCACAA-GAAAT-3Ј; and UCP3 reverse primer, 3Ј-ACGCAGAAA-GGAGGGCACAAAT-5Ј (UCP3 level͞18Sr RNA level). Intracellular cAMP and noradrenaline analyses were performed according to the protocol provided by the suppliers (cAMP detection kit from Amersham Pharmacia Biotech, Piscataway, NJ; and noradrenaline RIA kit from ALPCO, Windham, NH). Malonyl-CoA recycling assays were as described in ref. 4 
.
Animals. Male BALB͞c mice (8-9 weeks of age) were from Charles River Laboratories (Wilmington, MA) were maintained on a 12-h͞12-h light͞dark cycle, and they were fed rodent chow ad libitum. Three groups, C75-treated, refed (after fasting), and fasted, were subjected to a basic treatment protocol including an initial 23-h fast beginning at the start of the dark cycle followed by an i.c.v. injection of C75 (10 g) or vehicle. After injection, mice were given access to food (refed), or fasting was continued. Two hours later (generally), skeletal muscle was rapidly (30-60 s) removed for analysis. Propranolol (3 mg) was administered by i.p. injection. Procedures followed the guidelines of The Johns Hopkins University School of Medicine Institutional Animal Care and Use Committee.
